- Home
- CUE vs FORL Comparison
CUE vs FORL Comparison
Compare CUE & FORL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUE
- FORL
- Stock Information
- Founded
- CUE 2014
- FORL 2022
- Country
- CUE United States
- FORL United States
- Employees
- CUE N/A
- FORL N/A
- Industry
- CUE Biotechnology: Pharmaceutical Preparations
- FORL Blank Checks
- Sector
- CUE Health Care
- FORL Finance
- Exchange
- CUE Nasdaq
- FORL Nasdaq
- Market Cap
- CUE 37.0M
- FORL 44.8M
- IPO Year
- CUE 2018
- FORL 2023
- Fundamental
- Price
- CUE $0.59
- FORL $11.01
- Analyst Decision
- CUE Strong Buy
- FORL
- Analyst Count
- CUE 5
- FORL 0
- Target Price
- CUE $5.00
- FORL N/A
- AVG Volume (30 Days)
- CUE 221.5K
- FORL 8.4K
- Earning Date
- CUE 11-01-2024
- FORL 01-01-0001
- Dividend Yield
- CUE N/A
- FORL N/A
- EPS Growth
- CUE N/A
- FORL N/A
- EPS
- CUE N/A
- FORL 0.11
- Revenue
- CUE $8,295,000.00
- FORL N/A
- Revenue This Year
- CUE $104.90
- FORL N/A
- Revenue Next Year
- CUE N/A
- FORL N/A
- P/E Ratio
- CUE N/A
- FORL $102.84
- Revenue Growth
- CUE 363.67
- FORL N/A
- 52 Week Low
- CUE $0.56
- FORL $10.46
- 52 Week High
- CUE $3.25
- FORL $11.03
- Technical
- Relative Strength Index (RSI)
- CUE 35.76
- FORL 64.17
- Support Level
- CUE $0.58
- FORL $11.00
- Resistance Level
- CUE $0.70
- FORL $11.03
- Average True Range (ATR)
- CUE 0.09
- FORL 0.00
- MACD
- CUE -0.00
- FORL -0.00
- Stochastic Oscillator
- CUE 6.29
- FORL 60.00
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.
About FORL Four Leaf Acquisition Corporation
Four Leaf Acquisition Corp is a blank check company.